-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson Seeks FDA Approval for Caplyta in Bipolar Mania

PUBT·11/19/2026 13:07:37
Listen to the news
Johnson & Johnson Seeks FDA Approval for Caplyta in Bipolar Mania
  • Johnson & Johnson seeks FDA approval for Caplyta to treat manic or mixed episodes associated with bipolar I disorder in adults.
  • Two Phase 3 trials showed significant reductions in manic symptoms versus placebo by Day 3, sustained through Week 3.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: CG01545) on November 19, 2026, and is solely responsible for the information contained therein.